Cargando…
Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
SIMPLE SUMMARY: Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656699/ https://www.ncbi.nlm.nih.gov/pubmed/36358811 http://dx.doi.org/10.3390/cancers14215393 |
_version_ | 1784829501631365120 |
---|---|
author | Ramírez-Tortosa, César L. Alonso-Calderón, Rubén Gálvez-Navas, José María Pérez-Ramírez, Cristina Quiles, José Luis Sánchez-Rovira, Pedro Jiménez-Morales, Alberto Ramírez-Tortosa, MCarmen |
author_facet | Ramírez-Tortosa, César L. Alonso-Calderón, Rubén Gálvez-Navas, José María Pérez-Ramírez, Cristina Quiles, José Luis Sánchez-Rovira, Pedro Jiménez-Morales, Alberto Ramírez-Tortosa, MCarmen |
author_sort | Ramírez-Tortosa, César L. |
collection | PubMed |
description | SIMPLE SUMMARY: Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis, resulting in less differenced tumor cells and poorer prognosis, HIF-1α could be predictive of the tumor response to treatment. Nonetheless, very few studies have evaluated the predictive value of HIF-1α in breast cancer in patients receiving neoadjuvant chemotherapy. ABSTRACT: To demonstrate the value of hypoxia-inducible factor-1α (HIF-1α) in predicting response in patients with breast cancer receiving standard neoadjuvant chemotherapy (NAC). Methods: Ninety-five women enrolled in two prospective studies underwent biopsies for the histopathological diagnosis of breast carcinoma before receiving NAC, based on anthracyclines and taxanes. For expression of HIF-1α, EGFR, pAKT and pMAPK, tumor samples were analyzed by immunohistochemistry in tissues microarrays. Standard statistical methods (Pearson chi-square test, Fisher exact test, Kruskal–Wallis test, Mann–Whitney test and Kaplan–Meier method) were used to study the association of HIF-1α with tumor response, survival and other clinicopathologic variables/biomarkers. Results: HIF-1α expression was positive in 35 (39.7%) cases and was significantly associated to complete pathological response (pCR) (p = 0.014). HIF-1α expression was correlated positively with tumor grade (p = 0.015) and Ki-67 expression (p = 0.001) and negativity with progesterone receptors (PR) (p = 0.04) and luminal A phenotype expression (p = 0.005). No correlation was found between HIF-1α expression and EGFR, pAKT and pMAPK. In terms of survival, HIF-1α expression was associated with a significantly shorter disease-free survival (p = 0.013), being identified as an independent prognostic factor in multivariate analysis. Conclusions: Overexpression of HIF-1α is a predictor of pCR and shorter DFS; it would be valuable to confirm these results in prospective studies. |
format | Online Article Text |
id | pubmed-9656699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96566992022-11-15 Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy Ramírez-Tortosa, César L. Alonso-Calderón, Rubén Gálvez-Navas, José María Pérez-Ramírez, Cristina Quiles, José Luis Sánchez-Rovira, Pedro Jiménez-Morales, Alberto Ramírez-Tortosa, MCarmen Cancers (Basel) Article SIMPLE SUMMARY: Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis, resulting in less differenced tumor cells and poorer prognosis, HIF-1α could be predictive of the tumor response to treatment. Nonetheless, very few studies have evaluated the predictive value of HIF-1α in breast cancer in patients receiving neoadjuvant chemotherapy. ABSTRACT: To demonstrate the value of hypoxia-inducible factor-1α (HIF-1α) in predicting response in patients with breast cancer receiving standard neoadjuvant chemotherapy (NAC). Methods: Ninety-five women enrolled in two prospective studies underwent biopsies for the histopathological diagnosis of breast carcinoma before receiving NAC, based on anthracyclines and taxanes. For expression of HIF-1α, EGFR, pAKT and pMAPK, tumor samples were analyzed by immunohistochemistry in tissues microarrays. Standard statistical methods (Pearson chi-square test, Fisher exact test, Kruskal–Wallis test, Mann–Whitney test and Kaplan–Meier method) were used to study the association of HIF-1α with tumor response, survival and other clinicopathologic variables/biomarkers. Results: HIF-1α expression was positive in 35 (39.7%) cases and was significantly associated to complete pathological response (pCR) (p = 0.014). HIF-1α expression was correlated positively with tumor grade (p = 0.015) and Ki-67 expression (p = 0.001) and negativity with progesterone receptors (PR) (p = 0.04) and luminal A phenotype expression (p = 0.005). No correlation was found between HIF-1α expression and EGFR, pAKT and pMAPK. In terms of survival, HIF-1α expression was associated with a significantly shorter disease-free survival (p = 0.013), being identified as an independent prognostic factor in multivariate analysis. Conclusions: Overexpression of HIF-1α is a predictor of pCR and shorter DFS; it would be valuable to confirm these results in prospective studies. MDPI 2022-11-02 /pmc/articles/PMC9656699/ /pubmed/36358811 http://dx.doi.org/10.3390/cancers14215393 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ramírez-Tortosa, César L. Alonso-Calderón, Rubén Gálvez-Navas, José María Pérez-Ramírez, Cristina Quiles, José Luis Sánchez-Rovira, Pedro Jiménez-Morales, Alberto Ramírez-Tortosa, MCarmen Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy |
title | Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy |
title_full | Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy |
title_fullStr | Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy |
title_full_unstemmed | Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy |
title_short | Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy |
title_sort | hypoxia-inducible factor-1 alpha expression is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656699/ https://www.ncbi.nlm.nih.gov/pubmed/36358811 http://dx.doi.org/10.3390/cancers14215393 |
work_keys_str_mv | AT ramireztortosacesarl hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT alonsocalderonruben hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT galveznavasjosemaria hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT perezramirezcristina hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT quilesjoseluis hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT sanchezrovirapedro hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT jimenezmoralesalberto hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy AT ramireztortosamcarmen hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy |